<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642940</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-11</org_study_id>
    <nct_id>NCT01642940</nct_id>
  </id_info>
  <brief_title>Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study</brief_title>
  <official_title>Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single-center, single blind, investigator initiated, two&#xD;
      period study of crossover design. Diabetic patients with Acute Coronary Syndrome (ACS),&#xD;
      treated with oral and/or parenteral hypoglycaemic therapy for at least 1 month and subjected&#xD;
      to percutaneous coronary intervention (PCI), will be randomized after a baseline platelet&#xD;
      reactivity (PR) assessment (24 hours post PCI) while under clopidogrel in a 1:1 ratio to&#xD;
      either prasugrel 10mg or ticagrelor 180mg for 15 days followed by crossover directly to the&#xD;
      alternate therapy for an additional 15 days without an intervening washout period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>15 days</time_frame>
    <description>The primary outcome will be assessed 15 days after the onset of each study drug by the VerifyNow (Accumetrics)assay in platelet reactivity units (PRU)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyporesponsiveness rate (PRU≥230) at the end of the 2 treatment periods</measure>
    <time_frame>Day 15</time_frame>
    <description>Hyporesponsiveness rate will be assessed 15 days after the onset of each study drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 10mg/day</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90mg twice a day</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 75 years&#xD;
&#xD;
          -  Diabetic patients treated with oral and/or parenteral hypoglycaemic therapy for at&#xD;
             least 1 month&#xD;
&#xD;
          -  Patients with acute coronary syndrome subjected to PCI with a baseline PR evaluation&#xD;
             24 hours post PCI while on clopidogrel&#xD;
&#xD;
          -  Informed consent obtained in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with other investigational agents (including placebo) or devices within 30&#xD;
             days prior to randomization or planned use of investigational agents or devices prior&#xD;
             to the Day 30 visit.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Inability to give informed consent or high likelihood of being unavailable for the Day&#xD;
             30 follow up.&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Major periprocedural complications (death, stent thrombosis, vessel perforation,&#xD;
             arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous&#xD;
             antiarrhythmic agents, respiratory failure requiring intubation, vascular injury&#xD;
             (pseudoaneurysm, arteriovenous shunt, retroperitoneal bleeding or hematoma &gt;5 cm at&#xD;
             the arterial catheter insertion site), major bleeding (need for bood transfusion or&#xD;
             drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).&#xD;
&#xD;
          -  Unsuccessful PCI (residual stenosis &gt; 30% or flow &lt; ΤΙΜΙ 3) or planned staged PCI in&#xD;
             the next 30 days after randomization&#xD;
&#xD;
          -  Requirement for oral anticoagulant prior to the Day 30 visit&#xD;
&#xD;
          -  Current or planned therapy with other thienopyridine class of ADP receptor inhibitors.&#xD;
&#xD;
          -  Known hypersensitivity to prasugrel or ticagrelor&#xD;
&#xD;
          -  History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal&#xD;
             bleeding within the previous 6 months.&#xD;
&#xD;
          -  Other bleeding diathesis, or considered by investigator to be at high risk for&#xD;
             bleeding on longterm thienopyridine therapy.&#xD;
&#xD;
          -  Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm,&#xD;
             arteriovenous malformation, aneurysm).&#xD;
&#xD;
          -  Thrombocytopenia (&lt; 100.000/μL) at randomization&#xD;
&#xD;
          -  Anaemia (Hct &lt; 30%) at randomization&#xD;
&#xD;
          -  Polycytaemia (Hct &gt; 52%) at randomization&#xD;
&#xD;
          -  Periprocedural IIb/IIIa inhibitors administration&#xD;
&#xD;
          -  Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin&#xD;
             that cannot be adequately premedicated.&#xD;
&#xD;
          -  Recent (&lt; 6 weeks) major surgery or trauma, including GABG.&#xD;
&#xD;
          -  Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
             or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole,&#xD;
             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,&#xD;
             saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A&#xD;
             substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A&#xD;
             inducers (rifampin /rifampicin, phenytoin, carbamazepine).&#xD;
&#xD;
          -  Increased risk of bradycardiac events.&#xD;
&#xD;
          -  Dialysis required.&#xD;
&#xD;
          -  Age ≥ 75 years&#xD;
&#xD;
          -  Weight &lt; 60 Kg&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
&#xD;
          -  Severe uncontrolled chronic obstructive pulmonary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology Department Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>January 21, 2013</last_update_submitted>
  <last_update_submitted_qc>January 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor of Cardiology, Director of Cardiology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

